IL6R and familial pancreatic carcinoma: Given the detrimental effects of IL-6R blockade on TGFβ-specific immunity in pancreatic cancer observed in our preclinical studies and the sole distinction between patients in the CheckPAC and TRIPLE-R trials being tocilizumab treatment, we compared patients across the two studies to elucidate any impact of IL-6R blockade.